London
· Delayed Price · Currency is GBP · Price in USD Intellia Therapeutics Statistics
Total Valuation
LON:0JBU has a market cap or net worth of GBP 630.50 million. The enterprise value is 139.98 million.
| Market Cap | 630.50M |
| Enterprise Value | 139.98M |
Important Dates
The next estimated earnings date is Thursday, May 8, 2025.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +11.35% |
| Shares Change (QoQ) | +0.84% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 97.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.64 |
| PB Ratio | 0.91 |
| P/TBV Ratio | 0.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.34 |
| EV / Sales | 3.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.49 |
Financial Position
The company has a current ratio of 5.77, with a Debt / Equity ratio of 0.24.
| Current Ratio | 5.77 |
| Quick Ratio | 5.50 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.59 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.00% and return on invested capital (ROIC) is -29.71%.
| Return on Equity (ROE) | -54.00% |
| Return on Assets (ROA) | -26.80% |
| Return on Invested Capital (ROIC) | -29.71% |
| Return on Capital Employed (ROCE) | -49.46% |
| Revenue Per Employee | 114,716 |
| Profits Per Employee | -1.03M |
| Employee Count | 403 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.47% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -67.47% |
| 50-Day Moving Average | 8.98 |
| 200-Day Moving Average | 15.60 |
| Relative Strength Index (RSI) | 53.94 |
| Average Volume (20 Days) | 16,278 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.90 |
Income Statement
In the last 12 months, LON:0JBU had revenue of GBP 46.23 million and -414.58 million in losses. Loss per share was -4.19.
| Revenue | 46.23M |
| Gross Profit | -326.24M |
| Operating Income | -426.75M |
| Pretax Income | -414.58M |
| Net Income | -414.58M |
| EBITDA | -418.54M |
| EBIT | -426.75M |
| Loss Per Share | -4.19 |
Balance Sheet
The company has 480.47 million in cash and 167.90 million in debt, giving a net cash position of 520.42 million.
| Cash & Cash Equivalents | 480.47M |
| Total Debt | 167.90M |
| Net Cash | 520.42M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 696.49M |
| Book Value Per Share | 6.83 |
| Working Capital | 422.56M |
Cash Flow
In the last 12 months, operating cash flow was -278.67 million and capital expenditures -4.62 million, giving a free cash flow of -283.29 million.
| Operating Cash Flow | -278.67M |
| Capital Expenditures | -4.62M |
| Free Cash Flow | -283.29M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -923.10% |
| Pretax Margin | -896.77% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LON:0JBU does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.35% |
| Shareholder Yield | -11.35% |
| Earnings Yield | -65.75% |
| FCF Yield | -44.93% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0JBU has an Altman Z-Score of 0.64. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.64 |
| Piotroski F-Score | n/a |